Literature DB >> 8846482

Status of antimalarial drugs under development.

P L Olliaro1, P I Trigg.   

Abstract

Despite the urgent need of a new antimalarial drugs, particularly those against multiresistant falciparum malaria, only a limited number of drugs are now at an advanced stage of preclinical or clinical development. They include artemisinin derivatives, pyronaridine and benflumetol (all originally developed in China), as well as new antifolate combinations, the hydroxynaphoquinone atovaquone which has a novel mode of action, and a new 8-aminoquinoline which appears more active and less toxic than primaquine. Some of these drugs may become available in the next few years. It is therefore essential to find mechanisms to ensure that they are made available at an affordable price to the populations that really need them.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846482      PMCID: PMC2486827     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  25 in total

1.  Adverse reactions to sulfa drugs: implications for malaria chemotherapy.

Authors:  A Björkman; P A Phillips-Howard
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

2.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Authors:  P A Winstanley; W M Watkins; C R Newton; C Nevill; E Mberu; P A Warn; C M Waruiru; I N Mwangi; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

3.  Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine.

Authors:  A J Bitonti; A Sjoerdsma; P P McCann; D E Kyle; A M Oduola; R N Rossan; W K Milhous; D E Davidson
Journal:  Science       Date:  1988-12-02       Impact factor: 47.728

4.  The dihydrofolate reductase domain of Plasmodium falciparum thymidylate synthase-dihydrofolate reductase. Gene synthesis, expression, and anti-folate-resistant mutants.

Authors:  W Sirawaraporn; P Prapunwattana; R Sirawaraporn; Y Yuthavong; D V Santi
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

5.  New, antimalarial, tricyclic 1,2,4-trioxanes: evaluations in mice and monkeys.

Authors:  G H Posner; C H Oh; H K Webster; A L Ager; R N Rossan
Journal:  Am J Trop Med Hyg       Date:  1994-04       Impact factor: 2.345

6.  Efficacy of Ro 42-1611 (arteflene) in the treatment of patients with mild malaria: a clinical trial in Cameroon.

Authors:  R Somo-Moyou; M L Mittelholzer; F Sorenson; L Haller; D Stürchler
Journal:  Trop Med Parasitol       Date:  1994-09

7.  Tolerability and pharmacokinetics of Ro 42-1611 (arteflene) in man.

Authors:  E Weidekamm; E Dumont; C Jaquet
Journal:  Trop Med Parasitol       Date:  1994-09

8.  Reversal of chloroquine resistance in Plasmodium falciparum by verapamil.

Authors:  S K Martin; A M Oduola; W K Milhous
Journal:  Science       Date:  1987-02-20       Impact factor: 47.728

9.  Comparison of artemisinin suppositories with intravenous artesunate and intravenous quinine in the treatment of cerebral malaria.

Authors:  T T Hien; K Arnold; H Vinh; B M Cuong; N H Phu; T T Chau; N T Hoa; L V Chuong; N T Mai; N N Vinh
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

10.  Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity.

Authors:  G Watt; G W Long; M Grogl; S K Martin
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Mar-Apr       Impact factor: 2.184

View more
  15 in total

1.  In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.

Authors:  R N Price; J Marfurt; F Chalfein; E Kenangalem; K A Piera; E Tjitra; N M Anstey; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

2.  Comparative molecular field analysis of artemisinin derivatives: ab initio versus semiempirical optimized structures.

Authors:  S Tonmunphean; S Kokpol; V Parasuk; P Wolschann; R H Winger; K R Liedl; B M Rode
Journal:  J Comput Aided Mol Des       Date:  1998-07       Impact factor: 3.686

3.  Naphthylisoquinoline alkaloids against malaria: evaluation of the curative potentials of dioncophylline C and dioncopeltine A against Plasmodium berghei in vivo.

Authors:  G François; G Timperman; W Eling; L A Assi; J Holenz; G Bringmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Artemisinin derivatives for treating uncomplicated malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

5.  In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.

Authors:  L K Basco; J Bickii; P Ringwald
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.

Authors:  Innocent Mbulli Ali; Marie-Solange Bebandue Evehe; Palmer Masumbe Netongo; Barbara Atogho-Tiedeu; Mbuh Akindeh-Nji; Honore Ngora; Irenee Kamogne Domkam; Mahamadou Diakite; Khan Baldip; Lisa Ranford-Cartwright; Patrice Nsangou Mimche; Tracey Lamb; Wilfred Fon Mbacham
Journal:  Pathog Glob Health       Date:  2014-11-12       Impact factor: 2.894

7.  In vivo antimalarial activity of the beta-carboline alkaloid manzamine A.

Authors:  K K Ang; M J Holmes; T Higa; M T Hamann; U A Kara
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections.

Authors:  P Ringwald; J Bickii; A Same-Ekobo; L K Basco
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  Association of house spraying with suppressed levels of drug resistance in Zimbabwe.

Authors:  Sungano Mharakurwa; Susan L Mutambu; Robert Mudyiradima; Tawanda Chimbadzwa; Steven K Chandiwana; Karen P Day
Journal:  Malar J       Date:  2004-10-18       Impact factor: 2.979

10.  In Vitro Anti-plasmodial activity of Trigonella foenum-graecum L.

Authors:  M Palaniswamy; B V Pradeep; R Sathya; J Angayarkanni
Journal:  Evid Based Complement Alternat Med       Date:  2008-05-02       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.